Thus, our study calls for an urgent industry-academia collaborations to develop and validate SUMO2 isoform-specific inhibition strategies, which can target multiple hub pro-tumorigenic genes in glioblastoma pathology, irrespective of patient age and other clinicopathological parameters. Here, SUMO2 is linked to glioblastoma.